Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2011

Biogen Idec, Samsung Establish $300M Biosimilar Joint Venture

  • Biogen Idec and Samsung established a $300 million joint venture to develop and market biosimilars. The initiative, based in Korea, will be led by Samsung, which will contribute $225 million for an 85% stake. The venture will essentially contract with Biogen Idec and Samsung Biologics for technical development and manufacturing services, the firms state. However, it won't look to develop biosimilars of Biogen Idec’s proprietary products.

    Samsung Biologics was established in April 2011 to specialize in biopharmaceutical manufacturing. “This relationship will allow us to leverage our world-class protein engineering and biologics manufacturing capabilities, while maintaining focus on our mission of discovering, developing, and delivering innovative therapies for patients worldwide with neurodegenerative diseases, hemophilia, and autoimmune disorders,” comments George A. Scangos, Ph.D., Biogen Idec CEO. “We are very impressed with Samsung’s track record of leadership and excellence in all their businesses.” 

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »